The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Abstract
The body cholesterol pool increases with decreasing plasma-high-density-lipoprotein (H.D.L.) but is unrelated to the plasma concentrations of total cholesterol and other lipoproteins. This finding supports existing evidence that H.D.L. facilitates the uptake of cholesterol from peripheral tissues and its transport to the liver for catabolism and excretion. Plasma-H.D.L., is reduced in several conditions associated with an increased risk of future ischaemic heart-disease (I.H.D.), namely hypercholesterolaemia, hypertriglyceridaimia, male sex, obesity, and diabetes mellitus, while subjects with existing clinical I.H.D. have lower levels of H.D.L. than healthy subjects within the same community. It is proposed that a reduction of plasma-H.D.L. concentration may accelerate the development of atherosclerosis, and hence I.H.D., by impairing the clearance of cholesterol from the arterial wall.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is an inverse relationship between serum HDL levels and the risk of coronary heart disease49,50.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [49]
In the citing paper
“For many decades, a low level of HDL-C has been viewed as a robust and independent CVD risk factor1-4.”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [1]
Citations
Cites
The plasma lecithin:cholesterol acyltransferase reaction
Glomset, J. A. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43114-1 · Cited by 2,396
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
Kannel, W., Castelli, W., Gordon, T., & McNamara, P. M. (2020) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,160
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701052760107 · Cited by 1,911
ISCHÆMIC HEART-DISEASE IN RELATION TO FASTING VALUES OF PLASMA TRIGLYCERIDES AND CHOLESTEROL
Carlson, L., & Böttiger, L. E. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90738-6 · Cited by 752
PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS
Bang, H. O., Dyerberg, J., & Nielsen, A. B. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91658-8 · Cited by 690
Protein-lipid relationships in human plasma
Barr, D. P., Russ, E. M., & Eder, H. A. (1951) · The American Journal of Medicine · doi:10.1016/0002-9343(51)90183-0 · Cited by 635
RISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATES
Slack, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90930-1 · Cited by 625
PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS
Bang, H. O., Dyerberg, J., & Nielsen, A. B. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1986.tb07607.x · Cited by 604
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701192760305 · Cited by 526
VIGOROUS EXERCISE IN LEISURE-TIME AND THE INCIDENCE OF CORONARY HEART-DISEASE
Morris, J. N., Chave, S. P. W., Adam, C., Sirey, C., Epstein, L. H., & Sheehan, D. J. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90128-1 · Cited by 456
Research works printed but not linked: 13
- Miller, 1973, J. Lab. clin. Med., 82, 876
- Goodman, 1973, J. Lipid Res., 52, 2646
- Insull, 1968, J. Lab. clin. Med., 72, 885
- Schreibman, 1973, Clin. Res., 21, 638
- P. Clifton-Bligh, N.E. Miller, P.J. Nestel, Clin. Sci. ((in the press)).
- Nikkilä, 1953, Scand. J. clin. Lab. Invest., 5
- Fredrickson, 1968, J. clin. Invest., 47, 2446, 10.1172/JCI105927 · DOI
- N.E. Miller, P.J. Nestel, Eur. J. clin. Invest. ((in the press)).
- Kannel, 1962, Geriatrics, 17, 675
- Murphy, 1962, J. Lab. clin. Med., 60, 86
- Kudchodkar, 1972, Clin. Res., 20, 944
- Jones, 1970, J. Lab. clin. Med., 75, 953
- Bondjers, 1974, Proc. Eur. Soc. clin. Invest., 8, 123
Cited by
Sorted by citations
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,400
Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munafò, M. R., Palmer, T., Schooling, C. M., Wallace, C., Zhao, Q., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00092-5 · Cited by 2,229
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Metadata
- Authors
- Miller, G. J., & Miller, N. E.
- Affiliations
- University Hospital Llandough (GB)
- Edinburgh Royal Infirmary (GB)
- ORCID
- Miller, G.J
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1975-01
- Volume
- 305
- Issue
- 7897
- Pages
- 16-19
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1994967652
- Cited by
- 2,621
- References
- 59
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 9 · 2023: 7 · 2022: 15 · 2021: 17 · 2020: 24 · 2019: 18 · 2018: 18 · 2017: 17 · 2016: 29 · 2015: 29 · 2014: 22 · 2013: 32 · 2012: 26
- FWCI
- 157.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- high-density lipoprotein, ischemic heart disease, atherosclerosis, cholesterol metabolism, hypercholesterolemia, hypertriglyceridemia, obesity, diabetes mellitus, sex differences, cardiovascular risk factors
- MeSH terms
- Arteries, Arteriosclerosis, Cholesterol, Coronary Disease, Denmark, Inuit, Female, Finland, Humans, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Liver, Male, Middle Aged, Sex Factors, Sweden, Triglycerides, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review